Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.
Laura C. Michaelis, MD
Advertisement
Articles by Laura C. Michaelis, MD
Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.
Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.
Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.
Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.
Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Michaelis on Treating Patients With Myelofibrosis and AnemiaPublished: February 22nd 2020 | Updated:
Dr. Michaelis on Unanswered Questions in Myelofibrosis TreatmentPublished: April 10th 2020 | Updated:
Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in MyelofibrosisPublished: April 22nd 2020 | Updated:
Dr. Michaelis on the Role of Interferon in MPNsPublished: May 4th 2020 | Updated:
Dr. Michaelis on Fedratinib in Myelofibrosis TreatmentPublished: September 13th 2019 | Updated:
Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AMLPublished: June 21st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5